(New York, NY) – April 22, 2015 – AiCure, an artificial intelligence (AI) company in the life science sector, will be attending this year’s Partnerships in Clinical Trials in Boston. AiCure will be showcasing the technology at booth 110 – please stop by!
Clinical Research and Population Health Applications of AiCure’s Technology
Billion-dollar clinical trials fail when patients do not adhere to the treatment protocol. Inability to prove biological efficacy and understand the dose-response rate is the principal cause of failure in mid-late stage drug development. In population health, payers and governments spend $198 billion annually because of hospitalizations caused by non-adherence.
Researchers and providers rely on bioassays or directly watching the patient take their medication to confirm ingestion; however, limits on frequency of sampling and logistical and economic hurdles prevent these approaches from providing accurate day-to-day information.
AiCure has automated the process of directly monitoring patients by using artificial intelligence on mobile devices. The technology, available as an app on any smartphone, provides confirmed real-time dosing data on a centralized and cloud-based platform. The patented technology has been validated against pharmacokinetic (PK) data and shown to significantly improve adherence. AiCure’s technology is currently being employed in multiple trials and real-world settings across a wide variety of therapeutic areas